UCB And Analysts Believe Bimekizumab Will Be Super-Blockbuster

Having delivered on the clinical front with bimekizumab, UCB S.A. is fine-tuning its commercial strategy to set up the psoriasis drug as a mega-blockbuster despite entering a fiercely competitive space.

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion last month recommending marketing authorization for bimekizumab, the IL-17A and IL-17F inhibitor that the Belgian group will market as Bimzelx for the treatment of moderate-to-severe plaque psoriasis. The recommendation is based on three Phase III studies – BE VIVID, BE READY and BE SURE – which all hit their co-primary and ranked secondary endpoints and showed that patients treated with bimekizumab achieved superior levels of skin clearance at week 16 compared with those who received AbbVie Inc